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Summary NIH3T3 cells transfected with c-H-ras and/or c-myc genes were examined for differences in drug
sensitivity. The five transfectants used were N8, NIH3T3-nm-1, pT22-3-nm-2, pPl-4 and pT22-3. They were
transfected with pKOneo alone, pKOneo and c-myc, pKOneo and c-myc plus activated c-H-ras, normal
c-H-ras and activated c-H-ras genes, respectively. The IC50s of cisplatin, 4-hydroperoxycyclophosphamide,
adriamycin, melphalan, and CPT-11 were significantly higher for NIH3T3-nm-1 abd pT22-3-nm-2 than for the
parental NIH3T3 and N8 cells. Transfection with normal and activated C-H-ras oncogenes only led to
increases in the IC50s of alkylating agents. There was no significant difference between the IC5os of N8 and
those of NIH3T3 parental cells to any of these anticancer agents. These results strongly suggest that the
expression of the c-myc gene plays a role in the acquisition of drug resistance. The c-myc gene may therefore
provide us with an important clue in determining the mechanism of drug resistance.
The majority of malignant tumours are theoretically con-
sidered to be composed of both drug-sensitive and resistant
cells. If chemotherapeutic agents are administered, only the
drug-sensitive cells are removed. In addition, cells with
acquired resistance develop and after several courses of
chemotherapy only resistant cells are present. Accordingly,
inherent and acquired resistances are major causes of failure
in cancer chemotherapy. In order to elucidate the mechanism
of drug resistance, various biochemical and molecular bio-
logical investigations have been conducted. Among factors
which have been demonstrated to be related to drug resis-
tance are the following: (1) decreased drug uptake, (2) in-
creased drug efflux mediated by P-glycoprotein, (3) increased
intracellular detoxification by glutathione, metallothionein,
etc, (4) amplification of genes for the key enzymes of drug
metabolism, (5) decreased DNA damage and increased re-
pair, (6) activation of oncogenes. The relationship of some
genes to drug resistance has been directly demonstrated by
transfection studies (Sklar, 1988a,b). Examples of this are the
contribution of P-glycoprotein to multidrug resistance (Bell
et al., 1985; Ma et al., 1987; Bradley et al., 1989) and the
dihydrofolate reductase (DHFR) gene (Schimke, 1984) to
methotrexate resistance. However, there is little evidence
demonstrating a direct relationship between oncogenes and
drug resistance, although some oncogenes have been assoc-
iated with poor prognosis (Little et al., 1983; Nau et al.,
1985; Slamon et al., 1987). In order to study the contribu-
tions of oncogenes to drug resistance more directly, we have
determined by tetrazolium dye (MTT) assay, the drug sen-
sitivity of cells transfected with the c-myc and/or c-H-ras
oncogenes.
Materials and methods
Cell lines
NIH3T3 cells were used as the parental cell line. Transfection
with cloned oncogenes was performed by a modified calcium
precipitation method. For transfection with the c-myc onco-
gene we used the recombinant plasmid DNA designated
R-myc-27 cloned into the EcoRI PvuII region of pBR322,
propagated in Escherichia coli. R-myc-27 contained Sacd-
EcoRI 4 kb Shiraishi c-myc DNA (partially digested at the
3'-SacI site in the first intron of Shiraishi c-myc DNA)
containing the second and third exons that was ligated to the
PvuII-SacI 1.0 kb fragment of the Rous sarcoma virus long
terminal repeat (RSV-LTR) (Delorbe et al., 1980; Shibuya &
Yamaguchi, 1987; Rothberg et al., 1984). The cloned cell
line, which was cotransfected with pKOneo plasmid (Fasano
et al., 1984) and selected with 400fig ml' of G418 (Sigma,
MO), was designated NIH3T3-nm-1. pT22-3, the transfor-
mant obtained with the activated c-H-ras oncogenes, was
obtained by transfection of plasmid PT22 which was the
recombinant pBR322 containing activated human c-H-ras
gene cloned from T24 bladder carcinoma in BamHI site
(Santos et al., 1982; Fasano et al., 1984; Goldfarb et al.,
1982; Perucho et al., 1981). In addition, we obtained two
transfected cell lines, pT22-3-nm-2 and pPI-4, which were
transfected with activated c-H-ras plus c-myc and normal
c-H-ras genes, respectively. N8 was obtained by transfection
of pKOneo plasmid only and selected with G418. All the cell
lines used in this study were cultured in Dulbecco's modified
Eagle's medium (DMEM Nissui, Pharmaceutical Co Ltd.,
Tokyo) containing 10% heat-inactivated calf serum (GIBCO,
Grand Island, NY), penicillin (100 yml-') and streptomycin
(100lgml-') [c-DMEM] in a highly humidified atmosphere
of 5% CO2 plus 95% air at 37TC.
Cell line PC-9/CDDP, used as the positive control for
Glutathione S-Transferase-i gene expression (Fujiwara et al.,
1990), was established by exposure of PC-9, a non-small cell
lung cancer cell line, to stepwise increasing concentrations of
cisplatin (Hong et al., 1988). K562/ADM, an adriamycin
resistant human myelogenous leukaemia cell line, kindly pro-
vided by Dr T. Tsuruo, as the positive control for mdr-1
gene expression by Northern blot analysis. PC-9/CDDP cells
and K562/ADM cells were cultured in RPMI1640 medium
with 10% heat-inactivated fetal bovine serum (FBS, Im-
muno-Biological Laboratories, Fujioka, Japan), penicillin
(100 U ml-'), and streptomycin (100 lAg ml-') in a humidified
atmosphere of 5% CO2 plus 95% air at 37°C.
Characterisation ofcell lines
For the study of doubling times of these transfectants, a
single cell suspension containing 5 x 105 cells was placed into
60 mm dishes (Falcon, Becton Dickinson Laboware, Oxnard,
CA). Cells were counted daily for 6 days and the doubling
time of each cell line in its logarithmic phase was calculated.
For the evaluation of plating efficiency, single cell suspen-
sions were obtained by trypsinisation and diluted with c-
DMEM to the appropriate concentrations with the final cell
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numbers of 5 x 103 well for pT22-3-nm-2, pPl-4 and pT22-3,
and 1 x 104 well for NIH3T3, N8 and NIH3T3-nm-1. One
ml quantities of cell suspension in c-DMEM containing
0.06% agar (Difco Laboratories, Detroit, MI) were plated as
the bottom layer in 35 mm flat-bottomed wells of a tissue
culture multi-well plate (Linbro, Flow Laboratories Inc.,
McLean, VA). The bottom layer was prepared just before the
top layer was added. The top layer contained 0.35% agar in
enriched McCoy's 5A medium (Gibco, Grand Island, NY),
consisting of 50 ml of heat-inactivated foetal calf serum,
25 ml of heat-inactivated horse serum (GIBCO, NY), 4 ml of
2.2% sodium pyruvate, 4 ml of 200 mM glutamine, 0.8 ml of
2.1% serine and 5 ml of penicillin (100 U ml-') and strep-
tomycin (100 gg ml-') mixed with 400 ml McCoy's 5A
medium. After the top layer was added the plates were
incubated at 37'C in a humidified atmosphere of 5% CO2
plus 95% air for 10 days. Each experiment was performed in
triplicate and repeated three times. Colonies more than
50iLm in diameter were counted using an automatic particle
counter (CP-2000, Shiraimatsu, Osaka).
Southern blot analysis
Transfectants were tested for the presence of the transfected
genes by Southern blot analysis. DNAs were digested with
the BamHI or EcoRI restriction endonuclease for c-H-ras
and with EcoRI restriction endonuclease for c-myc under the
conditions directed by the manufacturer. Digested DNAs
were electrophoresed in 0.8% agarose and transferred to nit-
rocellulose membranes (Southern, 1975). We probed with a
1.5 kg Clal-EcoRI fragment for c-myc, a 3.0 kb SacI frag-
ment for c-myc and a 3.0 kb Sacd fragment for c-H-ras each
labelled with [a-32P]dCTP using the Multiprime DNA Label-
ling System (Amersham, Japan). Filters hybridised with
labelled probes were autoradiographed and developed (South-
ern, 1975).
Northern blot hybridisation analysis
Total RNA was prepared from the wild type NIH3T3,
NIH3T3-nm-1, pT22-3-nm, pPl-4, pT22-3, PC-9/CDDP and
K562/ADM cells by the acid guanidium thiocyanate-phenol-
chloroform extraction method (Chomczynski & Sacchi,
1986). Approximately 201tg of total RNA was electro-
phoresed and transferred to nitrocellulose filters (Maniatis et
al., 1982). We probed with a 0.4 kb PstI fragment containing
2nd exon of the human c-myc gene (Shibuya & Yamaguchi,
1987), a 3.0 kb SacI fragment of activated human c-H-ras
gene cloned from T24 bladder carcinoma (Viola et al., 1985),
pGPi2 coding for the human Glutathione Transferase (GST)-
T (Kano et al., 1987) and pMDR-I coding for the human
mdr-I gene (Roninson et al., 1986). All these probes were
labelled with [a-32P]dCTP to a specific activity of
2 x 108 cpm jig DNA using the Multiprime DNA Labelling
System (Amersham, Japan). Hybridisation was carried out
for 24 h under stringent conditions [5 x SSC (SSC; 150 mM
NaCI, 15 mM sodium citrate, pH 7.0), 50% formamide,
42'C]. After hybridisation, the filters were washed three times
in 0.1 x SSC containing 0.1% sodium dodecyl sulphate at
65'C for 15 min. The filter was autoradiographed at - 70'C.
Testfor sensitivity ofNIH3T3 cells and transfectants
Cells of each clone were plated in 60 mm petri dishes (Corn-
ing Glass Works, Corning, NY) with 5 ml of DMEM con-
taining 10% calf serum (GIBCO) and 0.27 g of glutamine
(Nissui, Japan) for the determination of plating efficiency.
Foci were counted at confluent growth. The MTT assay
(Mosmann, 1983) was used to test for sensitivity to cisplatin
(CDDP, Bristol-Myers K.K., Tokyo), adriamycin (ADR,
Kyowa Hakko Kogyo Co Ltd, Tokyo), 4-hydroperoxy cyclo-
phosphamide (hCPA, a metabolite of cyclophosphamide,
Shionogi Co Ltd, Osaka), etoposide (VP-16, Bristol-Myers
K.K., Tokyo), (4S)-4, 11-diethyl-4-hydroxy-9-[(4-piperidino-
piperidino)carbonyloxy]-lH-pyrano[3',4': 6, 7] indolizino[1,2-
b] quinoline-3, 14(4H, 12H)-dione hydrochloride trihydrate
(CPT-l Yakult Co Ltd., Tokyo) and melphalan (Sumitomo
Chemical Co Ltd., Tokyo). In the case of NIH3T3, N8 and
NIH-3T3-nm-1 (Table I), 1 x i03 cells/well with 180 l1 of
culture medium were plated in a culture plate (Falcon 3072
96-well tissue culture plate), and for pT22-3-nm-2, pPl-4 and
pT22-3, 5 x 102 cells/well were plated with 180f.l of medium
in the culture plate. Twenty iLl of drug solution was added to
each well. After 4 days of incubation at 37°C, the plate was
centrifuged at 1,200 r.p.m. for 5 min and the medium was
aspirated from the wells as completely as possible. To each
well 200tl of dimethyl sulfoxide (Wako Pure Chemical
Industries Ltd., Osaka) was added. The plates were then
agitated on a plate shaker for 5 min and the optical density
was read using a Titertek Multiscan MCC plate reader (Flow
Laboratories). The absorbance for wells containing drug to
that of the control well.
Results
Characteristics oftransfectants
Morphologically the c-H-ras transfectants (pT22-3, pT22-3-
nm-2 and pPl-4) were transformed but NIH3T-nm-1, trans-
fected with c-myc alone, was not. N8, transfected with
pKOneo plasmid, was also not transformed. NIH3T3, N8
and NIH3T3-nm-1 did not produce any foci, although pT22-
3-nm-2, pP1-4 and pT22-3 did. In agreement with this
finding, in the study of plating efficiency by the soft agar
double layer method (Table I), pT22-3-nm-2, pPl-4 and
pT22-3 produced colonies although NIH3T3, N8 and
NIH3T3-nm-I did not. Doubling times of these transfectants
were in the range 15 to 23 h.
Figure 1 shows the presence of the c-myc gene in NIH3T3-
nm-i and pT22-3-nm-2 cells transfected with this gene, and
the c-H-ras gene in pPl-4, pT22-3 and pT22-3-nm-2 cells
transfected with this gene as determined by Southern blot
analysis. Figure 2 shows the results of Northern blot analysis
of NIH3T3 cells and the four transfectants. NIH3T3-nm-1
and pT22-3-nm-2 expressed the c-myc gene and pT22-3-nm-2,
pPl-4 and pT22-3 expressed the c-H-ras gene. The right hand
side of Figure 2 shows the expression of B-actin gene mRNA
among the cells lines. Figure 3 demonstrates the expressions
of GST-rc and mdr-l genes in parental NIH3T3 cells and
transfectants together with the positive controls. PC-9/CDDP
Table I Characteristics of the cells
Characteristics
Cells Oncogenes Plating efficiency (%) Doubling time (h)
NIH3T3 0 22
N8 0 23
nm-1a c-myc 0 22
nm-2b c-myc 21 15
activated c-H-ras
pPl-4 normal c-H-ras 20 15
pT22-3 activated c-H-ras 17 18
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Figure 1 Southern blot analysis of NIH3T3 cells and transfec-
tions. Tengg of DNA from each cell line was digested with left,
EcoRI; middle, BamHI; right, EcoRI and hybridised with
[a32P]dCTP labelled probes, 1.5 kb Clal EcoRI RI fragment for
c-myc and 3.0 kb Sac I fragment for c-H-ras. The molecular sizes
(kb) are indicated on the right. Lane 1, NIH3T3 cells; Lane 2,
pPl-4 cells; Lane 3, pT22-3 cells; Lane 4, NIH3T3-nm-1 cells;
Lane 5, pT22-3-nm-2 cells.
Drug sensitivity oftransfectants
Figures 4 and 5 show representative response curves for each
cell line exposed to hCPA and melphalan. The cell lines
transfected with the c-myc oncogene are more resistant than
the parental NIH3T3 and N8 cells to these two agents. Each
curve was obtained from the average of at least three
independent experiments and the IC-% (the concentration of
drug which reduces the cell growth to 50% of control) for
each cell line was calculated as the average of at least three
independently-obtained IC,,s. Table II summarises the IC. s
of various drugs for all the cell lines. N8, transfected with
pKOneo only, showed no significant difference in IC,,s com-
pared with those of NIH3T3 cells to any of the anticancer
agents. The cell lines transfected with the c-myc gene
(NIH3T3-nm-l and pT22-3-nm-2) were significantly more
resistant than in the NIH3T3 and N8 cell line to cisplatin,
melphalan, adriamycin, 4-hydroperoxycyclophosphamide,
and CPT-l . With VP-16 there was no significant difference
in IC50s between any of the transfectants and NIH3T3 cells,
but a trend towards resistance was obtained. The cell lines
transfected with c-H-ras oncogene (pPl-4 and pT22-3)
showed no significant difference in IC"s compared with
NIH3T3 and N8 cells to cisplatin and topoisomerase
0
0
10
0.01 0.1 1 10
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Figure 4 Sensitivity of NIH3T3 cells and transfectants to 4-
hydroperoxycyclophosphamide. The symbols used in this figure
are as follows: -A- NIH3T3; *A- N8; -0- NIH3T3-
nm-I; 0- pT22-3-nm-2.
100*
12 3 4 5 1 2 3 4 5
24-
2.0kb
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c-H-ras 0-actin
Figure 2 Northern blot analysis of NIH3T3 cells and transfec-
tants. Twenty1tg of total RNA from each cell line was prepared,
electrophoresed, transferred to nitrocellulose membrane, hybrid-
ised with the human c-myc gene; c-H-ras gene; P-actin gene. Lane
1, NIH3T3 cells; Lane 2, pPl-4 cells; Lane 3, pT22-3 cells; Lane
4, NIH3T3-nm-1 cells; Lane 5, pT22-3-nm-2 cells.
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Figure 3 Expression of Glutathione S-Transferase-n gene and
mdr-l gene by Northern blot analysis. Lane 1, NIH3T3 cells;
Lane 2, pPl-4 cells; Lane 3, pT22-3 cells; Lane 4, NIH3T3-nm-l
cells; Lane 5, pT22-3-nm-2 cells; Lane 6, PC-9/CDDP cells; Lane
7, K562/ADM cells.
and K562/ADM as positive controls showed the expressions
of the GST-x (at 0.8 kb) and mdr-l (at 4.5 kb) genes, respec-
tively. In contrast NIH3T3 cells and transfectants showed
negligible expressions of both GST-7i and mdr-l genes.
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Figure 5 Sensitivity of NIH3T3 cells and transfections to mel-
phalan. The symbols used are as follows: -A- NIH3T3;
-A- N8; -0- NIH3T3-nm-l; -0- pT22-3-nm-2.
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Table II IC50 values of anticancer drugs for transfectants
IC50 values (pgml11)a
Cells CDDP hCPA Melphalan ADR VP-16 CPT-1J
NIH3T3 0.21 ± 0.03b 0.34 ± 0.02 0.95 ± 0.05 0.21 ± 0.03 0.06 ± 0.01 9.64 + 0.26
N8C 0.26 ± 0.09 0.59 ± 0.15 1.20 ± 0.43 0.22 ± 0.06 0.04 ± 0.03 9.09 ± 0.82
nm-Id 0.44 ± 0.03f 1.60 ± 0.18' 4.63 ± 0.918 0.34 ± 0.03g 0.07 ± 0.01 16.2 3.25h
nm-2e 0.34 ± 0.04g 1.11 ± 0.37h 8.60 ±0.20 0.46 ± 0.06g 0.21 ± 0.20 21.2 +0.739
pPl-4 0.26 ± 0.02 0.60 ± 0.098 15.40 ± 1.54h 0.12 ± 0.02 0.06 ± 0.01 9.07 ± 1.51
pT22-3 0.11+ 0.01± 0.71 ± 0.03w 2.67 ± 0.61 0.07 ± 0.01 0.04 ± 0.00 7.07 + 0.67
'IC50 values are obtained as the concentrations which inhibit control cell growth by 50%; bMean ± s.d. Values
were calculated from the results obtained by at lest three independent experiments; CN8 cell line was obtained by the
transfection of pKOneo plasmid alone to NIH3T3 cells; dNIH3T3-nm-1; epT2203-nm-2; fp<0.001; gp<0.01; hp < 0.05.
inhibitors (adriamycin, VP-16 and CPT-11). With alkylating
agents (hCPA and melphalan) the transfectants with c-H-ras
had higher ICm values than those of the parental and N8
cells, although that for melphalan in pT22-3 was not
significantly different. From these results it is concluded that
(1) c-myc oncogenes increased the intrinsic resistance to the
anticancer agents, cisplatin, 4-hydroperoxycyclophosphamide,
adriamycin, melphalan and CPT-1 1 and (2) c-H-ras onco-
genes increased resistance to alkylating agents only (3) G418
selection did not lead to the isolation of resistant clones
which had activated various stress response genes.
Discussion
The MTT assay has the advantage of short incubation time
and simplicity. The assay can reflect both cytotoxic and
growth inhibitory effect of anticancer agents, but, with longer
cell doubling times, it mainly reflects cytotoxic effect. It is
therefore important to determine the plated cell numbers and
the incubation time in order to achieve an optimal evaluation
of drug sensitivity. Following determination that each cell
line could maintain linearity in its growth curve and yield
accurate reproducibility of optical density, we decided to use
a 4-day incubation period and different plating cell numbers,
as described in Materials and methods.
All transfectants used in this study were obtained from the
same parental NIH3T3 cells. Cells transfected with the c-myc
oncogene acquired resistance to anticancer agents in that IC,o
values for all the drugs except VP-16 in nm-I and nm-2 were
significantly higher than those in parental NIH3T3 and N8
cells. Transfection of activated c-H-ras did not affect drug
sensitivity in nm-2 considering that IC50 values of pT22-3,
transfected with activated c-H-ras, were not higher than
those of NIH3T3 and N8 cells except for hCPA. In the two
c-myc expressing lines (nm-I and nm-2) there is a large
difference in the amount of c-myc mRNA expressed, but no
difference in the degree of drug resistance. One possible
explanation for this observation is that the cotransfection of
activated c-H-ras gene in nm-2 has some influence on drug
sensitivity in this line. Another possibility is that there is a
threshold in the amount of c-myc gene expression which
influences drug sensitivity and that subclone variation does
not always give rise to the difference in drug resistance
among transfectants. We obtained another c-myc transfected
cell line (nm-9) by the same procedure and this showed about
the same IC50 values to CDDP, hCPA, VP-16 and CPT- 11 as
those for nm-i. Moreover the IC50 value of nm-9 for mel-
phalan was 2.3 times higher than that of nm-I and 9.8 times
higher than that of the parental cells. These findings confirm
that independently isolated c-myc subclones show the aquisi-
tion of resitance to CDDP, hCPA, melphalan and CPT-l1
compared with the parental and pKOneo transfected cells.
Further study is necessary to examine the correlation
between drug resistance and the expression of c-myc
oncogene by using not cotransfectants but a range of trans-
fectants with different amounts of c-myc oncogene alone.
In order to determine how we can overcome resistance to
anticancer agents, the genetic basis of such resistance is the
most urgent issue that needs addressing (Anonymous, 1987;
Busch, 1987). With regard to myc family genes, amplification
of the N-myc oncogene is associated with rapid progression
in neuroblastoma (Seeger et al., 1985).
Additionally small cell lung cancer patients have a shorter
survival period if their cells show c-myc gene amplification,
and c-myc amplification is associated with a more virulent
variant type of small cell lung cancer cell line (Johnson et al.,
1987b). Such cell lines transfected with c-myc oncogene show
morphological changes in culture (Johnson et al., 1986) and
have shorter doubling times (Gazdar et al., 1985). These
observations therefore suggest that myc family genes are
associated with some biological characteristics of malignant
tumours, but do not directly prove that these genes contri-
bute to the resistance to anticancer drugs. In the present
study we have clearly demonstrated that transfection with the
c-myc gene is associated with increased resistance to cisplatin,
adriamycin, melphalan, CPT-11 and 4-hydroperoxycyclo-
phosphamide.
This is the first report showing that c-myc oncogene can
increase resistance to anticancer agents and there have been
no reports to elucidate the mechanism of increase in drug
resistance by c-myc oncogenes. It has been reported that
transfection with the c-H-ras gene could increase the resis-
tance to cisplatin and radiation in cell lines (Sklar, 1988a,b).
On the other hand Toffoli et al. (1989) reported that transfec-
tion with H-ras did not induce resistance to CDDP, VP-16,
Mitomycin C on adriamycin. In the present study we have
demonstrated that the cell lines transfected with the c-H-ras
gene increased resistance to some alkylating agents, but not
to cisplatin, VP-16 and adriamycin. Although we have no
data for Mitomycin C, our findings are not always inconsis-
tent with the results of Toffoli. Previous findings have sug-
gested that a mechanism of resistance to anticancer agents
might be a decrease in intracellular accumulation of drugs.
On the other hand, as in v-H-ras oncogene-transfected cells
(Burt et al., 1988), c-myc oncogenes might increase the ex-
pression of other genes known to be involved in drug resis-
tance. There have been some reports that the overexpression
of the GDT-s gene is associated with the acquisition of
resistance to cisplatin (Nakagawa et al., 1988) and
adriamycin (Cowan, 1986). Our results in Table II show that
nm-1 transfected with c-myc oncogene acquired a multidrug
resistance phenotype. However, no apparent expression of
GST-i and mdr-I genes could be found in NIH3T3 cells or
any of the transfectants. These results therefore indicate that
resistance to anticancer agents in c-myc transfected cells can-
not be explained by mdr-I and GST-i gene expression. The
c-myc transfected cell lines acquired higher resistance to
alkylating agents than to other drugs (Table II, Figures 4 and
5). Considering that the target of alkylating agents is mainly
DNA in the cell nucleus and that c-myc protein is primarily
located in the nucleus, we are planning to study the
accumulation of anticancer agents and examine DNA
damage and repair in c-myc transfected cells as possible
mechanisms of resistance.
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